Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 386

1.

Evidence for increased completed suicide in first-degree relatives of LRRK2 G2019S mutation Parkinson's disease.

Ortega RA, Groves M, Mirelman A, Alcalay RN, Raymond D, Elango S, Mejia-Santana H, Giladi N, Marder K, Bressman SB, Saunders-Pullman R.

J Neurol Neurosurg Psychiatry. 2018 Nov 8. pii: jnnp-2018-319364. doi: 10.1136/jnnp-2018-319364. [Epub ahead of print] No abstract available.

PMID:
30409888
2.

The transition between turning and sitting in patients with Parkinson's disease: A wearable device detects an unexpected sequence of events.

Weiss A, Herman T, Mirelman A, Shiratzky SS, Giladi N, Barnes LL, Bennett DA, Buchman AS, Hausdorff JM.

Gait Posture. 2018 Oct 21;67:224-229. doi: 10.1016/j.gaitpost.2018.10.018. [Epub ahead of print]

PMID:
30380506
3.

Single center experience with medical cannabis in Gilles de la Tourette syndrome.

Thaler A, Arad S, Schleider LB, Knaani J, Taichman T, Giladi N, Gurevich T.

Parkinsonism Relat Disord. 2018 Oct 1. pii: S1353-8020(18)30429-2. doi: 10.1016/j.parkreldis.2018.10.004. [Epub ahead of print]

PMID:
30292733
4.

Survival rates among Parkinson's disease patients who carry mutations in the LRRK2 and GBA genes.

Thaler A, Kozlovski T, Gurevich T, Bar-Shira A, Gana-Weisz M, Orr-Urtreger A, Giladi N, Mirelman A.

Mov Disord. 2018 Oct;33(10):1656-1660. doi: 10.1002/mds.27490. Epub 2018 Oct 4.

PMID:
30288804
5.

Depressive symptoms may increase the risk of the future development of freezing of gait in patients with Parkinson's disease: Findings from a 5-year prospective study.

Herman T, Shema-Shiratzky S, Arie L, Giladi N, Hausdorff JM.

Parkinsonism Relat Disord. 2018 Sep 11. pii: S1353-8020(18)30398-5. doi: 10.1016/j.parkreldis.2018.09.013. [Epub ahead of print]

PMID:
30236826
6.

Dysphagia characteristics in Huntington's disease patients: insights from the Fiberoptic Endoscopic Evaluation of Swallowing and the Swallowing Disturbances Questionnaire.

Manor Y, Oestreicher-Kedem Y, Gad A, Zitser J, Faust-Socher A, Shpunt D, Naor S, Inbar N, Kestenbaum M, Giladi N, Gurevich T.

CNS Spectr. 2018 Sep 10:1-6. doi: 10.1017/S1092852918001037. [Epub ahead of print]

PMID:
30198457
7.

FDG PET Parkinson's disease-related pattern as a biomarker for clinical trials in early stage disease.

Matthews DC, Lerman H, Lukic A, Andrews RD, Mirelman A, Wernick MN, Giladi N, Strother SC, Evans KC, Cedarbaum JM, Even-Sapir E.

Neuroimage Clin. 2018 Aug 10;20:572-579. doi: 10.1016/j.nicl.2018.08.006. eCollection 2018.

8.

Higher serum cholesterol and decreased Parkinson's disease risk: A statin-free cohort study.

Rozani V, Gurevich T, Giladi N, El-Ad B, Tsamir J, Hemo B, Peretz C.

Mov Disord. 2018 Aug;33(8):1298-1305. doi: 10.1002/mds.27413. Epub 2018 Aug 25.

PMID:
30145829
9.

Increased substantia nigra echogenicity in LRRK2 family members without mutations.

Pullman M, Ortega R, Glickman A, Deik A, Raymond D, Marder K, Giladi N, Bressman S, Hagenah J, Brüggemann N, Saunders-Pullman R.

Mov Disord. 2018 Sep;33(9):1504-1505. doi: 10.1002/mds.27443. Epub 2018 Aug 25. No abstract available.

PMID:
30145825
10.

What predicts falls in Parkinson disease?: Observations from the Parkinson's Foundation registry.

Parashos SA, Bloem BR, Browner NM, Giladi N, Gurevich T, Hausdorff JM, He Y, Lyons KE, Mari Z, Morgan JC, Post B, Schmidt PN, Wielinski CL.

Neurol Clin Pract. 2018 Jun;8(3):214-222. doi: 10.1212/CPJ.0000000000000461. Erratum in: Neurol Clin Pract. 2018 Aug;8(4):278.

PMID:
30105161
11.

Altered reward-related neural responses in non-manifesting carriers of the Parkinson disease related LRRK2 mutation.

Thaler A, Gonen T, Mirelman A, Helmich RC, Gurevich T, Orr-Urtreger A, Bloem BR, Giladi N, Hendler T; LRRK2 Ashkenazi Jewish consortium.

Brain Imaging Behav. 2018 Jul 3. doi: 10.1007/s11682-018-9920-2. [Epub ahead of print]

PMID:
29971685
12.

Pace of movement: the role of single neurons in the subthalamic nucleus.

Tankus A, Mirelman A, Giladi N, Fried I, Hausdorff JM.

J Neurosurg. 2018 Jun 22:1-6. doi: 10.3171/2018.1.JNS171859. [Epub ahead of print]

PMID:
29932375
13.

SPARC: a new approach to quantifying gait smoothness in patients with Parkinson's disease.

Beck Y, Herman T, Brozgol M, Giladi N, Mirelman A, Hausdorff JM.

J Neuroeng Rehabil. 2018 Jun 18;15(1):49. doi: 10.1186/s12984-018-0398-3.

14.

Consensus for the measurement of the camptocormia angle in the standing patient.

Margraf NG, Wolke R, Granert O, Berardelli A, Bloem BR, Djaldetti R, Espay AJ, Fasano A, Furusawa Y, Giladi N, Hallett M, Jankovic J, Murata M, Tinazzi M, Volkmann J, Berg D, Deuschl G.

Parkinsonism Relat Disord. 2018 Jul;52:1-5. doi: 10.1016/j.parkreldis.2018.06.013. Epub 2018 Jun 8.

PMID:
29907329
15.

Cerebral Imaging Markers of GBA and LRRK2 Related Parkinson's Disease and Their First-Degree Unaffected Relatives.

Thaler A, Kliper E, Maidan I, Herman T, Rosenberg-Katz K, Bregman N, Gurevich T, Shiner T, Hausdorff JM, Orr-Urtreger A, Giladi N, Mirelman A.

Brain Topogr. 2018 Nov;31(6):1029-1036. doi: 10.1007/s10548-018-0653-8. Epub 2018 May 30.

PMID:
29846835
16.

Parkinson's disease phenotype is influenced by the severity of the mutations in the GBA gene.

Thaler A, Bregman N, Gurevich T, Shiner T, Dror Y, Zmira O, Gan-Or Z, Bar-Shira A, Gana-Weisz M, Orr-Urtreger A, Giladi N, Mirelman A.

Parkinsonism Relat Disord. 2018 Oct;55:45-49. doi: 10.1016/j.parkreldis.2018.05.009. Epub 2018 May 17.

PMID:
29784561
17.

Model-based and Model-free Machine Learning Techniques for Diagnostic Prediction and Classification of Clinical Outcomes in Parkinson's Disease.

Gao C, Sun H, Wang T, Tang M, Bohnen NI, Müller MLTM, Herman T, Giladi N, Kalinin A, Spino C, Dauer W, Hausdorff JM, Dinov ID.

Sci Rep. 2018 May 8;8(1):7129. doi: 10.1038/s41598-018-24783-4.

18.

Basal ganglia and beyond: The interplay between motor and cognitive aspects in Parkinson's disease rehabilitation.

Ferrazzoli D, Ortelli P, Madeo G, Giladi N, Petzinger GM, Frazzitta G.

Neurosci Biobehav Rev. 2018 Jul;90:294-308. doi: 10.1016/j.neubiorev.2018.05.007. Epub 2018 May 4. Review.

19.

Treadmill walking reduces pre-frontal activation in patients with Parkinson's disease.

Thumm PC, Maidan I, Brozgol M, Shustak S, Gazit E, Shema Shiratzki S, Bernad-Elazari H, Beck Y, Giladi N, Hausdorff JM, Mirelman A.

Gait Posture. 2018 May;62:384-387. doi: 10.1016/j.gaitpost.2018.03.041. Epub 2018 Mar 28.

PMID:
29626840
20.

Application of the Movement Disorder Society prodromal criteria in healthy G2019S-LRRK2 carriers.

Mirelman A, Saunders-Pullman R, Alcalay RN, Shustak S, Thaler A, Gurevich T, Raymond D, Mejia-Santana H, Orbe Reilly M, Ozelius L, Clark L, Gana-Weisz M, Bar-Shira A, Orr-Utreger A, Bressman SB, Marder K, Giladi N; AJ LRRK2 Consortium.

Mov Disord. 2018 Jul;33(6):966-973. doi: 10.1002/mds.27342. Epub 2018 Mar 30.

PMID:
29603409
21.

Evidence for Differential Effects of 2 Forms of Exercise on Prefrontal Plasticity During Walking in Parkinson's Disease.

Maidan I, Nieuwhof F, Bernad-Elazari H, Bloem BR, Giladi N, Hausdorff JM, Claassen JAHR, Mirelman A.

Neurorehabil Neural Repair. 2018 Mar;32(3):200-208. doi: 10.1177/1545968318763750. Epub 2018 Mar 16.

PMID:
29546797
22.

How attention modulates encoding of dynamic stimuli in older adults.

Oren N, Shapira-Lichter I, Lerner Y, Hendler T, Giladi N, Ash EL.

Behav Brain Res. 2018 Jul 16;347:209-218. doi: 10.1016/j.bbr.2018.02.031. Epub 2018 Feb 25.

PMID:
29490234
23.

Effectiveness of a Goal-Based Intensive Rehabilitation in Parkinsonian Patients in Advanced Stages of Disease.

Ortelli P, Ferrazzoli D, Bera R, Caremani L, Giladi N, Maestri R, Frazzitta G.

J Parkinsons Dis. 2018;8(1):113-119. doi: 10.3233/JPD-171247.

PMID:
29480227
24.

Prefrontal cortex activation during obstacle negotiation: What's the effect size and timing?

Maidan I, Shustak S, Sharon T, Bernad-Elazari H, Geffen N, Giladi N, Hausdorff JM, Mirelman A.

Brain Cogn. 2018 Apr;122:45-51. doi: 10.1016/j.bandc.2018.02.006. Epub 2018 Feb 15.

PMID:
29454975
25.

Who will remain tremor dominant? The possible role of cognitive reserve in the time course of two common Parkinson's disease motor subtypes.

Herman T, Shema-Shiratzky S, Arie L, Giladi N, Hausdorff JM.

J Neural Transm (Vienna). 2018 Jun;125(6):1007-1011. doi: 10.1007/s00702-018-1859-3. Epub 2018 Feb 15.

PMID:
29450651
26.

Multitarget transcranial direct current stimulation for freezing of gait in Parkinson's disease.

Dagan M, Herman T, Harrison R, Zhou J, Giladi N, Ruffini G, Manor B, Hausdorff JM.

Mov Disord. 2018 Apr;33(4):642-646. doi: 10.1002/mds.27300. Epub 2018 Feb 13.

27.

Progression in the LRRK2-Asssociated Parkinson Disease Population.

Saunders-Pullman R, Mirelman A, Alcalay RN, Wang C, Ortega RA, Raymond D, Mejia-Santana H, Orbe-Reilly M, Johannes BA, Thaler A, Ozelius L, Orr-Urtreger A, Marder KS, Giladi N, Bressman SB; LRRK2 Ashkenazi Jewish Consortium.

JAMA Neurol. 2018 Mar 1;75(3):312-319. doi: 10.1001/jamaneurol.2017.4019.

PMID:
29309488
28.

Sex differences in LRRK2 G2019S and idiopathic Parkinson's Disease.

San Luciano M, Wang C, Ortega RA, Giladi N, Marder K, Bressman S, Saunders-Pullman R; Michael J Fox Foundation LRRK2 Consortium.

Ann Clin Transl Neurol. 2017 Oct 19;4(11):801-810. doi: 10.1002/acn3.489. eCollection 2017 Nov.

29.

Age-associated changes in obstacle negotiation strategies: Does size and timing matter?

Maidan I, Eyal S, Kurz I, Geffen N, Gazit E, Ravid L, Giladi N, Mirelman A, Hausdorff JM.

Gait Posture. 2018 Jan;59:242-247. doi: 10.1016/j.gaitpost.2017.10.023. Epub 2017 Oct 27.

PMID:
29096267
30.

Medical Cannabis in Parkinson Disease: Real-Life Patients' Experience.

Balash Y, Bar-Lev Schleider L, Korczyn AD, Shabtai H, Knaani J, Rosenberg A, Baruch Y, Djaldetti R, Giladi N, Gurevich T.

Clin Neuropharmacol. 2017 Nov/Dec;40(6):268-272. doi: 10.1097/WNF.0000000000000246.

PMID:
29059132
31.

Validation of the Hebrew version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale.

Zitser J, Peretz C, Ber David A, Shabtai H, Ezra A, Kestenbaum M, Brozgol M, Rosenberg A, Herman T, Balash Y, Gadoth A, Thaler A, Stebbins GT, Goetz CG, Tilley BC, Luo ST, Liu Y, Giladi N, Gurevich T.

Parkinsonism Relat Disord. 2017 Dec;45:7-12. doi: 10.1016/j.parkreldis.2017.09.012. Epub 2017 Sep 24.

32.

Disparate effects of training on brain activation in Parkinson disease.

Maidan I, Rosenberg-Katz K, Jacob Y, Giladi N, Hausdorff JM, Mirelman A.

Neurology. 2017 Oct 24;89(17):1804-1810. doi: 10.1212/WNL.0000000000004576. Epub 2017 Sep 27.

PMID:
28954877
33.

Do cognition and other non-motor symptoms decline similarly among patients with Parkinson's disease motor subtypes? Findings from a 5-year prospective study.

Arie L, Herman T, Shema-Shiratzky S, Giladi N, Hausdorff JM.

J Neurol. 2017 Oct;264(10):2149-2157. doi: 10.1007/s00415-017-8605-x. Epub 2017 Sep 6.

PMID:
28879438
34.

Reduced mind wandering in patients with Parkinson's disease.

Geffen T, Thaler A, Gilam G, Ben Simon E, Sarid N, Gurevich T, Giladi N, Shabtai H, Zitser J, Schilman EA, Sharon H.

Parkinsonism Relat Disord. 2017 Nov;44:38-43. doi: 10.1016/j.parkreldis.2017.08.030. Epub 2017 Sep 1.

PMID:
28877857
35.

Two Ethnic Clusters with Huntington Disease in Israel: The Case of Mountain Jews and Karaites.

Zitser J, Thaler A, Inbar N, Gad A, Faust-Socher A, Paleacu D, Anca-Herschkovitch M, Balash Y, Shabtai H, Ash EL, Merkin L, Manor Y, Kestenbaum M, Bar David A, Peretz C, Naiman T, Bar-Shira A, Orr-Urtreger A, Dangoor N, Giladi N, Gurevich T.

Neurodegener Dis. 2017;17(6):281-285. doi: 10.1159/000479375. Epub 2017 Aug 25.

PMID:
28848105
36.

Schema benefit vs. proactive interference: Contradicting behavioral outcomes and coexisting neural patterns.

Oren N, Shapira-Lichter I, Lerner Y, Tarrasch R, Hendler T, Giladi N, Ash EL.

Neuroimage. 2017 Sep;158:271-281. doi: 10.1016/j.neuroimage.2017.07.006. Epub 2017 Jul 5.

PMID:
28689053
37.

Estimation of genetic risk function with covariates in the presence of missing genotypes.

Lee AJ, Marder K, Alcalay RN, Mejia-Santana H, Orr-Urtreger A, Giladi N, Bressman S, Wang Y.

Stat Med. 2017 Sep 30;36(22):3533-3546. doi: 10.1002/sim.7376. Epub 2017 Jun 27.

38.

Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry.

Lee AJ, Wang Y, Alcalay RN, Mejia-Santana H, Saunders-Pullman R, Bressman S, Corvol JC, Brice A, Lesage S, Mangone G, Tolosa E, Pont-Sunyer C, Vilas D, Schüle B, Kausar F, Foroud T, Berg D, Brockmann K, Goldwurm S, Siri C, Asselta R, Ruiz-Martinez J, Mondragón E, Marras C, Ghate T, Giladi N, Mirelman A, Marder K; Michael J. Fox LRRK2 Cohort Consortium.

Mov Disord. 2017 Oct;32(10):1432-1438. doi: 10.1002/mds.27059. Epub 2017 Jun 22.

39.

The role of the prefrontal cortex in freezing of gait in Parkinson's disease: insights from a deep repetitive transcranial magnetic stimulation exploratory study.

Dagan M, Herman T, Mirelman A, Giladi N, Hausdorff JM.

Exp Brain Res. 2017 Aug;235(8):2463-2472. doi: 10.1007/s00221-017-4981-9. Epub 2017 May 16.

PMID:
28509934
40.

When is Higher Level Cognitive Control Needed for Locomotor Tasks Among Patients with Parkinson's Disease?

Maidan I, Bernad-Elazari H, Giladi N, Hausdorff JM, Mirelman A.

Brain Topogr. 2017 Jul;30(4):531-538. doi: 10.1007/s10548-017-0564-0. Epub 2017 Apr 24.

PMID:
28439757
41.

Effects of aging on prefrontal brain activation during challenging walking conditions.

Mirelman A, Maidan I, Bernad-Elazari H, Shustack S, Giladi N, Hausdorff JM.

Brain Cogn. 2017 Jul;115:41-46. doi: 10.1016/j.bandc.2017.04.002. Epub 2017 Apr 21.

PMID:
28433922
42.

Focused and Sustained Attention Is Modified by a Goal-Based Rehabilitation in Parkinsonian Patients.

Ferrazzoli D, Ortelli P, Maestri R, Bera R, Gargantini R, Palamara G, Zarucchi M, Giladi N, Frazzitta G.

Front Behav Neurosci. 2017 Mar 31;11:56. doi: 10.3389/fnbeh.2017.00056. eCollection 2017.

43.

DaT-SPECT assessment depicts dopamine depletion among asymptomatic G2019S LRRK2 mutation carriers.

Artzi M, Even-Sapir E, Lerman Shacham H, Thaler A, Urterger AO, Bressman S, Marder K, Hendler T, Giladi N, Ben Bashat D, Mirelman A.

PLoS One. 2017 Apr 13;12(4):e0175424. doi: 10.1371/journal.pone.0175424. eCollection 2017.

44.

Gently does it: Humans outperform a software classifier in recognizing subtle, nonstereotypical facial expressions.

Yitzhak N, Giladi N, Gurevich T, Messinger DS, Prince EB, Martin K, Aviezer H.

Emotion. 2017 Dec;17(8):1187-1198. doi: 10.1037/emo0000287. Epub 2017 Apr 13.

PMID:
28406679
45.

Statin adherence and the risk of Parkinson's disease: A population-based cohort study.

Rozani V, Giladi N, El-Ad B, Gurevich T, Tsamir J, Hemo B, Peretz C.

PLoS One. 2017 Apr 7;12(4):e0175054. doi: 10.1371/journal.pone.0175054. eCollection 2017.

46.

A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease.

Olanow CW, Kieburtz K, Leinonen M, Elmer L, Giladi N, Hauser RA, Klepiskaya OS, Kreitzman DL, Lew MF, Russell DS, Kadosh S, Litman P, Friedman H, Linvah N, The P B Study Group F.

Mov Disord. 2017 May;32(5):783-789. doi: 10.1002/mds.26941. Epub 2017 Apr 3.

PMID:
28370340
47.

Clinical Practice: Evidence-Based Recommendations for the Treatment of Cervical Dystonia with Botulinum Toxin.

Contarino MF, Van Den Dool J, Balash Y, Bhatia K, Giladi N, Koelman JH, Lokkegaard A, Marti MJ, Postma M, Relja M, Skorvanek M, Speelman JD, Zoons E, Ferreira JJ, Vidailhet M, Albanese A, Tijssen MA.

Front Neurol. 2017 Feb 24;8:35. doi: 10.3389/fneur.2017.00035. eCollection 2017. Review.

48.

Neural patterns underlying the effect of negative distractors on working memory in older adults.

Oren N, Ash EL, Tarrasch R, Hendler T, Giladi N, Shapira-Lichter I.

Neurobiol Aging. 2017 May;53:93-102. doi: 10.1016/j.neurobiolaging.2017.01.020. Epub 2017 Feb 3.

PMID:
28242539
49.

Subthalamic Neurons Encode Both Single- and Multi-Limb Movements in Parkinson's Disease Patients.

Tankus A, Strauss I, Gurevich T, Mirelman A, Giladi N, Fried I, Hausdorff JM.

Sci Rep. 2017 Feb 13;7:42467. doi: 10.1038/srep42467.

50.

A "dose" effect of mutations in the GBA gene on Parkinson's disease phenotype.

Thaler A, Gurevich T, Bar Shira A, Gana Weisz M, Ash E, Shiner T, Orr-Urtreger A, Giladi N, Mirelman A.

Parkinsonism Relat Disord. 2017 Mar;36:47-51. doi: 10.1016/j.parkreldis.2016.12.014. Epub 2016 Dec 16.

PMID:
28012950

Supplemental Content

Loading ...
Support Center